Module 8: Questions on Management and Treatment: Side Effects and Drug Interactions
This learning activity has been designated for 1.50 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in this activity.
Learning Objectives
After completing this educational activity, the learner should be better able to:
- Explain the importance of treating patients with chronic myeloid leukemia (CML) experiencing a suboptimal response to treatment according to the accepted guidelines
- Assess response to treatment in patients with CML
- Identify patients with CML who are not responding optimally to treatment
- Formulate an alternative treatment plan for patients whose first-line therapy has failed or who have had a suboptimal response to first-line therapy
Target Audience
This learning activity is intended for medical oncologists, hematologists, stem cell transplant physicians, and other interested healthcare professionals who manage and treat chronic myelogenous leukemia in the hematology/oncology and transplant patient settings.
Release Date: November 30, 2008
Expiration date: November 30, 2009
(*Please check this box to proceed - required)
Start the Module